WCN26-6813 PEGCETACOPLAN FOR 52-WEEKS MAINTAINED PROTEINURIA REDUCTION REGARDLESS OF IMMUNOSUPPRESSANT USE OR NEPHROTIC RANGE PROTEINURIA AT BASELINE: VALIANT SUBGROUP ANALYSIS

Read full text Summarise with VIRAT
Authors: Carla Nester, Fádi Fakhouri
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pegcetacoplan, a targeted C3/C3b inhibitor, may prevent the deposition of C3 breakdown products, thereby reducing glomerular inflammation and kidney damage in patients with C3 glomerulopathy (C3G) or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis (IC-MPGN). VALIANT (Phase 3; NCT05067127) evaluated the efficacy and safety of pegcetacoplan in adolescents (≥12 years) and adults with native or post-transplant C3G or primary IC-MPGN.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106280–106280
Publication date
25 March 2026
Language
EN